The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, as compared with docetaxel in this patient population. METHODS: We randomly assigned 272 patients to receive nivolumab, at a dose of 3 mg per kilogram of body weight every 2 weeks, or docetaxel, at a dose of 75 mg per square meter of body-surface area every 3 weeks. The primary end point was overall survival. RESULTS: The median overall survival was 9.2 months (95% confidence interval [CI], 7.3 to 13.3) with nivolumab versus 6.0 months (95% CI, 5.1 to 7.3) with docetaxel. The risk of death was 41% lower with nivolumab than with docetaxel (hazard ratio, 0.59; 95% CI, 0.44 to 0.79; P<0.001). At 1 year, the overall survival rate was 42% (95% CI, 34 to 50) with nivolumab versus 24% (95% CI, 17 to 31) with docetaxel. The response rate was 20% with nivolumab versus 9% with docetaxel (P=0.008). The median progression-free survival was 3.5 months with nivolumab versus 2.8 months with docetaxel (hazard ratio for death or disease progression, 0.62; 95% CI, 0.47 to 0.81; P<0.001). The expression of the PD-1 ligand (PD-L1) was neither prognostic nor predictive of benefit. Treatment-related adverse events of grade 3 or 4 were reported in 7% of the patients in the nivolumab group as compared with 55% of those in the docetaxel group. CONCLUSIONS: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level. (Funded by Bristol-Myers Squibb; CheckMate 017 ClinicalTrials.gov number, NCT01642004.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nivolumab has significantly improved outcomes in patients with metastatic non-small cell lung cancer (NSCLC); however, reliable prognostic biomarkers remain an unmet need.”
From SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“The development of immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 interaction has transformed the therapeutic landscape of patients with advanced non-small cell lung cancer (NSCLC) [1][2][3][4][5][6] .”
From Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) · cites this paper as [2]
In the citing paper
“Landmark trials performed on previously treated patients with advanced NSCLC demonstrated superior overall survival (OS) with PD-1/PD-L1 blockade compared to standard chemotherapy [1][2][3] .”
From Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) · cites this paper as [2]
In the citing paper
“Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [72]
In the citing paper
“At the data cut-off, median OS was 9.2 months (95% CI: 7.3-13.3months) on nivolumab compared with 6.0 months (95% CI: 5.1-7.3months) on docetaxel, with a 41% reduction in the risk of death in the nivolumab arm (HR 0.59, 95% CI: 0.44-0.49;P < 0.001).”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“The expression of PD-L1 was neither prognostic nor predictive of clinical benefit in a retrospective analysis using various cut points in this study.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“A phase III trial (CheckMate 017) in patients previously treated for SCC compared 3 mg/kg of nivolumab given every 2 weeks with docetaxel, showing an improvement of 3.2 months [97,98]”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“In the phase III trial, nivolumab was better tolerated than docetaxel, with 85% of nivolumab patients receiving at least 90% of their planned dose intensity, compared with 69% of docetaxel patients, together with a treatment discontinuation rate of 10% versus 3% of the patients treated with nivolumab and docetaxel, respectively.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“The primary end point was overall response rate, which occurred in 17 (14.5%) of 117 patients (95% CI 8.7 to 22.2).”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
In the citing paper
“Median time to response was 3.3 months; median duration of response had not been reached at the time of publication.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
In the citing paper
“Adverse effects included dyspnea, fatigue, pneumonitis, diarrhea, musculoskeletal pain, and severe immune-mediated adverse effects98,99; 59% of patients experienced serious adverse events.100”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Self-citationHanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Flagged first, then by citations
Research works printed but not linked: 1
- Soria JC, 2013, Eur J Cancer, 49
Cited by
Sorted by citations
Items 601–700 of 1,048
Nanotechnology in the diagnosis and treatment of lung cancer
Cryer, A. M., & Thorley, A. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.010 · Cited by 177
Fumet, J.-D., Richard, C., Ledys, F., Klopfenstein, Q., Joubert, P., Routy, B., Truntzer, C., Gagné, A., Hamel, M.-A., Guimaraes, C. F., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0220-9 · Cited by 176
Uryvaev, A., Passhak, M., Hershkovits, D., Sabo, E., & Bar‐Sela, G. (2018) · Medical Oncology · doi:10.1007/s12032-018-1080-0 · Cited by 176
Boussios, S., Seraj, E., Zarkavelis, G., Petrakis, D., Kollas, A., Kafantari, A., Assi, A., Tatsi, K., Pavlidis, N. A., & Pentheroudakis, G. E. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.006 · Cited by 175
Blumenthal, G. M., Gong, Y., Kehl, K. L., Mishra-Kalyani, P. S., Goldberg, K. B., Khozin, S., Kluetz, P. G., Oxnard, G. R., & Pazdur, R. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz060 · Cited by 175
Magee, D., Hird, A. E., Klaassen, Z. W. A., Sridhar, S. S., Nam, R. K., Wallis, C. J. D., & Kulkarni, G. S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.008 · Cited by 175
Lee, J. B., Kim, H. R., & Ha, S. (2022) · Immune Network · doi:10.4110/in.2022.22.e2 · Cited by 175
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 176
Bamodu, O. A., Kuo, K.-T., Wang, C., Huang, W.-C., Wu, A. T. H., Tsai, J.-T., Lee, K.-Y., Yeh, C., & Wang, L.-S. (2019) · Nutrients · doi:10.3390/nu11102264 · Cited by 174
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Sato, H., Okonogi, N., & Nakano, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01666-1 · Cited by 175
Xu, X., Lv, J., Guo, F., Li, J., Jia, Y., Jiang, D., Wang, N., Zhang, C., Kong, L., Liu, Y., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00814 · Cited by 173
“, 2015) and non-small cell lung cancer (Brahmer et al., 2015).”
BackgroundNSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis
Lurienne, L., Cervesi, J., Duhalde, L., de Gunzburg, J., Andremont, A., Zalcman, G., Buffet, R., & Bandinelli, P.-A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.002 · Cited by 174
Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer
Inoue, Y., Yoshimura, K., Kurabe, N., Kahyo, T., Kawase, A., Tanahashi, M., Ogawa, H., Inui, N., Funai, K., Shinmura, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14434 · Cited by 172
Suh, K. J., Kim, S. H., Kim, Y. J., Kim, M., Keam, B., Kim, T. M., Kim, D., Heo, D. S., & Lee, J. S. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2092-x · Cited by 172
Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy
Shevtsov, M. A., Sato, H., Multhoff, G., & Shibata, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00156 · Cited by 173
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
Dougan, M. L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01547 · Cited by 171
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
Costantini, A., Julié, C., Duménil, C., Hélias‐Rodzewicz, Z., Tisserand, J. C., Dumoulin, J., Giraud, V., Labrune, S., Chinet, T., Emile, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1452581 · Cited by 171
Assoun, S., Théou–Anton, N., Nguenang, M., Cazes, A., Danel, C. J., Abbar, B., Pluvy, J., Gounant, V., Khalil, A., Namour, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.005 · Cited by 171
Avery, L., Filderman, J. N., Szymczak-Workman, A. L., & Kane, L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712107115 · Cited by 171
Jelinic, P., Ricca, J. M., Oudenhove, E. V., Olvera, N., Merghoub, T., Levine, D. A., & Zamarin, D. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx277 · Cited by 171
Advances in Cancer Immunotherapy in Solid Tumors
Menon, S. P., Shin, S. J., & Dy, G. K. (2016) · Cancers · doi:10.3390/cancers8120106 · Cited by 170
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
Mushtaq, M. U., Papadas, A., Pagenkopf, A. C., Flietner, E., Morrow, Z. T., Chaudhary, S. G., & Asimakopoulos, F. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0376-0 · Cited by 170
Bilen, M. A., Martini, D. J., Liu, Y., Lewis, C. M., Collins, H., Shabto, J. M., Akce, M., Kissick, H. T., Carthon, B. C., Shaib, W. L., et al. (2018) · Cancer · doi:10.1002/cncr.31778 · Cited by 170
written on behalf of AME Lung Cancer Collaborative Group, Xu, Y., Wan, B., Chen, X., Zhan, P., Zhao, Y., Zhang, T., Liu, H., Afzal, M. Z., Dermime, S., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.09 · Cited by 170
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Yonesaka, K., Haratani, K., Takamura, S., Sakai, H., Kato, R., Takegawa, N., Takahama, T., Tanaka, K., Hayashi, H., Takeda, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2852 · Cited by 169
Russo, A., Russano, M., Franchina, T., Migliorino, M. R., Aprile, G., Mansueto, G., Berruti, A., Falcone, A., Aieta, M., Gelibter, A. J., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01229-w · Cited by 169
Ferrara, R., Naigeon, M., Auclin, É., Duchemann, B., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Desnoyer, A., Mezquita, L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1420 · Cited by 169
Self-citationSantoni, M., Rizzo, A., Mollica, V., Matrana, M. R., Rosellini, M., Faloppi, L., Marchetti, A., Battelli, N., & Massari, F. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103596 · Cited by 169
Kim, S., Koh, J., Kim, M., Kwon, D., Go, H., Kim, Y. A., Jeon, Y. K., & Chung, D. H. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.07.007 · Cited by 168
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Anagnostou, V., Yarchoan, M. M., Hansen, A. R., Wang, H., Verde, F., Sharon, E., Collyar, D. E., Chow, L. Q. M., & Forde, P. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3065 · Cited by 168
Applications and strategies in nanodiagnosis and nanotherapy in lung cancer
Woodman, C. B. J., Vundu, G., George, A., & Wilson, C. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.009 · Cited by 168
Shi, T., Song, X., Wang, Y., Liu, F., & Wei, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00683 · Cited by 168
Choucair, K., Morand, S. M., Stanbery, L., Edelman, G. M., Dworkin, L. D., & Nemunaitis, J. J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 170
Udager, A. M., Liu, T., Skala, S. L., Magers, M. J., McDaniel, A. S., Spratt, D. E., Feng, F. Y.-C., Siddiqui, J., Cao, X., Fields, K. L., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw216 · Cited by 167
Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease
Hiley, C. T., Quesne, J. P. C. L., Santis, G., Sharpe, R., de Castro, D. G., Middleton, G., & Swanton, C. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31340-x · Cited by 167
Rehman, J., Han, G., Carvajal‐Hausdorf, D., Wasserman, B. E., Pelekanou, V., Mani, N. L., McLaughlin, J. F., Schalper, K. A., & Rimm, D. L. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.186 · Cited by 167
Pinto, J. A., Vallejos, C. S., Raez, L. E., Mas, L. A., Ruiz, R., Torres-Román, J. S., Morante, Z., Araujo, J. M., Gómez, H., Aguilar, A., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000344 · Cited by 167
Shiroyama, T., Nagatomo, I., Koyama, S., Hirata, H., Nishida, S., Miyake, K., Fukushima, K., Shirai, Y., Mitsui, Y., Takata, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39120-6 · Cited by 167
Singh, M. P., Rai, S., Pandey, A., Singh, N. K., & Srivastava, S. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.10.013 · Cited by 167
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
Passiglia, F., Bronte, G., Bazan, V., Natoli, C., Rizzo, S., Galvano, A., Listì, A., Cicero, G., Rolfo, C. D., Santini, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7582 · Cited by 166
Strategies for Increasing Pancreatic Tumor Immunogenicity
Johnson, B. A., Yarchoan, M. M., Lee, V., Laheru, D. A., & Jaffee, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2318 · Cited by 166
Mushti, S. L., Mulkey, F. A., & Sridhara, R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1902 · Cited by 166
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Landi, L. M., Federica D’Incà, Gelibter, A. J., Chiari, R., Grossi, F., Delmonte, A., Passaro, A., Signorelli, D., Gelsomino, F., Galetta, D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0793-8 · Cited by 166
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Herzberg, B., Campo, M. J., & Gainor, J. F. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0189 · Cited by 165
Self-citationAutoantibodies: Opportunities for Early Cancer Detection
Macdonald, I. K., Parsy-Kowalska, C. B., & Chapman, C. J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.02.003 · Cited by 165
Update on Immunohistochemistry for the Diagnosis of Lung Cancer
Inamura, K. (2018) · Cancers · doi:10.3390/cancers10030072 · Cited by 167
MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells
Stutvoet, T. S., Kol, A., de Vries, E. G. E., de Bruyn, M., Fehrmann, R. S. N., van Scheltinga, A. G. T. T., & de Jong, S. (2019) · The Journal of Pathology · doi:10.1002/path.5280 · Cited by 165
Zhao, S., Gao, G., Li, W., Li, X., Zhao, C., Jiang, T., Jia, Y., He, Y., Li, A., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.017 · Cited by 164
Kinoshita, T., Muramatsu, R., Fujita, T., Nagumo, H., Sakurai, T., Noji, S., Takahata, E., Yaguchi, T., Tsukamoto, N., Kudo‐Saito, C., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw319 · Cited by 164
Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
Lee, C., Yelensky, R., Jooss, K. U., & Chan, T. A.-T. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.005 · Cited by 164
Gori, S., Inno, A., Belluomini, L., Bocus, P., Bisoffi, Z., Russo, A. D., & Arcaro, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.003 · Cited by 164
Ferrara, R., Mezquita, L., Auclin, E., Chaput, N., & Besse, B. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.003 · Cited by 163
Aguiar, P. N., Santoro, I. L., Tadokoro, H., Lopes, G. D. L., Jr., Filardi, B. A., Oliveira, P. F., Mountzios, G., & de Mello, R. A. (2016) · Immunotherapy · doi:10.2217/imt-2015-0002 · Cited by 163
Danilova, L., Wang, H., Sunshine, J. C., Kaunitz, G. J., Cottrell, T. R., Xu, H., Esandrio, J., Anders, R. A., Cope, L., Pardoll, D. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607836113 · Cited by 164
Abdel-Rahman, O. M., Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mannhart, M., Mehrabi, A., Schöb, O. M., & Giryes, A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1296765 · Cited by 163
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
Abu‐Sbeih, H., Tang, T., Lü, Y., Thirumurthi, S., Altan, M., Jazaeri, A. A., Dadu, R., Coronel, E. S., & Wang, Y. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0502-7 · Cited by 163
Felip, E., Ardizzoni, A., Ciuleanu, T., Cobo, M., Лактионов, К. К., Szilasi, M., Califano, R., Carcereny, E., Griffiths, R., Paz-Ares, L. G., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.019 · Cited by 163
Self-citationMollica, V., Rizzo, A., Marchetti, A., Tateo, V., Tassinari, E., Rosellini, M., Massafra, R., Santoni, M., & Massari, F. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01159-1 · Cited by 163
Park, H. J., Kim, K. W., Pyo, J., Suh, C. H., Yoon, S., Hatabu, H., & Nishino, M. (2020) · Radiology · doi:10.1148/radiol.2020200443 · Cited by 162
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma
Kim, C., Kim, E., Jung, H., Chon, H. J., Han, J. W., Shin, K.-H., Hu, H., Kim, K. S., Choi, Y. D., Kim, S., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2451-6 · Cited by 162
Pseudoprogression and hyperprogression after checkpoint blockade
Wang, Q., Gao, J., & Wu, X. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.03.018 · Cited by 162
Su, Q., Zhu, E. C., Wu, J., Li, T., Hou, Y., Wang, D., & Gao, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00108 · Cited by 162
Wang, Q., Li, M., Yang, M., Yang, Y., Song, F., Zhang, W., Li, X., & Chen, K. (2020) · Aging · doi:10.18632/aging.102814 · Cited by 164
Cardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 161
Li, W., Wu, F., Zhao, S., Shi, P., Wang, S., & Cui, D. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.004 · Cited by 161
Böhm, S., Montfort, A., Pearce, O. M. T., Topping, J. H., Chakravarty, P., Everitt, G. L. A., Clear, A. J., McDermott, J. R., Ennis, D. P., Dowe, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2657 · Cited by 160
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab
Peters, S., Kerr, K. M., & Stahel, R. A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.002 · Cited by 160
Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer
Hendry, S. A., Byrne, D. J., Wright, G. M., Young, R. J., Sturrock, S., Cooper, W. A., & Fox, S. B. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.112 · Cited by 160
Spigel, D. R., Chaft, J. E., Gettinger, S. N., Chao, B. H., Dirix, L. Y., Schmid, P., Chow, L. Q. M., Hicks, R. J., Leon, L., Fredrickson, J. O., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.004 · Cited by 160
Self-citationFaruki, H., Mayhew, G. M., Serody, J. S., Hayes, D. N., Perou, C. M., & Lai-Goldman, M. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.03.010 · Cited by 159
PD-L1 expression testing in non-small cell lung cancer
Teixidó, C., Vilariño, N., Reyes, R., & Reguart, N. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918763493 · Cited by 159
Mechanisms and Therapy for Cancer Metastasis to the Brain
Franchino, F., Rudà, R., & Soffietti, R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00161 · Cited by 160
Kimbara, S., Fujiwara, Y., Iwama, S., Ohashi, K., Kuchiba, A., Arima, H., Yamazaki, N., Kitano, S., Yamamoto, N., & Ohe, Y. (2018) · Cancer Science · doi:10.1111/cas.13800 · Cited by 158
Immune checkpoint inhibition in ovarian cancer
Hamanishi, J., Mandai, M., & Konishi, I. (2016) · International Immunology · doi:10.1093/intimm/dxw020 · Cited by 158
Kirilovsky, A., Marliot, F., Sissy, C. E., Haicheur, N., Galon, J., & Pagès, F. (2016) · International Immunology · doi:10.1093/intimm/dxw021 · Cited by 159
Cha, Y. J., Kim, H. R., Lee, C. Y., Cho, B. C., & Shim, H. S. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.001 · Cited by 158
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
Shimoji, M., Shimizu, S., Sato, K., Suda, K., Kobayashi, Y., Tomizawa, K., Takemoto, T., & Mitsudomi, T. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.021 · Cited by 158
Comorbidities in the management of patients with lung cancer
Leduc, C., Antoni, D., Charloux, A., Falcoz, P., & Quoix, É. (2017) · European Respiratory Journal · doi:10.1183/13993003.01721-2016 · Cited by 158
Khunger, M., Hernández, A. V., Pasupuleti, V., Rakshit, S., Pennell, N. A., Stevenson, J. P., Mukhopadhyay, S., Schalper, K. A., & Velcheti, V. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00030 · Cited by 158
Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis
Buchhalter, I., Rempel, E., Endris, V., Allgäuer, M., Neumann, O., Volckmar, A., Kirchner, M., Leichsenring, J., Lier, A., von Winterfeld, M., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31878 · Cited by 158
Proto, C., Ferrara, R., Signorelli, D., Russo, G. L., Galli, G., Imbimbo, M., Prelaj, A., Zilembo, N., Ganzinelli, M., Pallavicini, L. M., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.03.004 · Cited by 158
Self-citationEmerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 159
Synthetic lethality-mediated precision oncology via the tumor transcriptome
Lee, J. S., Nair, N. U., Dinstag, G., Chapman, L. M., Chung, Y., Wang, K., Sinha, S., Cha, H., Kim, D., Schperberg, A. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.030 · Cited by 158
Parra, E. R., Villalobos, P. A., Mino, B., & Rodriguez‐Canales, J. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000531 · Cited by 157
Targeting immune checkpoints in breast cancer: an update of early results
Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 157
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
Tan, A. C., Emmett, L., Lo, S., Liu, V., Kapoor, R., Carlino, M. S., Guminski, A. D., Long, G. V., & Menzies, A. M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy330 · Cited by 157
Brueckl, W. M., Ficker, J. H., & Zeitler, G. (2020) · BMC Cancer · doi:10.1186/s12885-020-07690-8 · Cited by 159
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
To, K. K. W., Fong, W., & Cho, W. C. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.635007 · Cited by 157
Sceneay, J., Goreczny, G. J., Wilson, K., Morrow, S., DeCristo, M. J., Ubellacker, J. M., Qin, Y., Laszewski, T., Stover, D. G., Barrera, V., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1454 · Cited by 156
Nghiem, P., Kaufman, H. L., Bharmal, M. F., Mahnke, L. A., Phatak, H. M., & Becker, J. C. (2017) · Future Oncology · doi:10.2217/fon-2017-0072 · Cited by 156
Immune checkpoint inhibitors in cancer therapy
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 119
Kim, J. Y., Kronbichler, A., Eisenhut, M., Hong, S. H., van der Vliet, H. J., Kang, J., Shin, J. I., & Gamerith, G. (2019) · Cancers · doi:10.3390/cancers11111798 · Cited by 158
Gandara, D. R., von Pawel, J., Mazières, J., Sullivan, R., Helland, Å., Han, J., Ponce-Aix, S., Rittmeyer, A., Barlési, F., Kubo, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2027 · Cited by 155
Nanomedicine and macroscale materials in immuno-oncology
Sun, Q., Barz, M., Geest, B. G. D., Diken, M., Hennink, W. E., Kiessling, F. M., Lammers, T., & Shi, Y. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00473k · Cited by 155
Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer
Tang, C., Hobbs, B., Amer, A., Li, X., Behrens, C., Canales, J. R., Cuentas, E. P., Villalobos, P., Fried, D., Chang, J. Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20471-5 · Cited by 154
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
Liniker, E., Menzies, A. M., Kong, B. Y., Cooper, A. J., Ramanujam, S., Lo, S., Kefford, R. F., Fogarty, G. B., Guminski, A. D., Wang, W., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1214788 · Cited by 154
Okita, R., Maeda, A., Shimizu, K., Nojima, Y., Saisho, S., & Nakata, M. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1986-y · Cited by 154
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives
Ventriglia, J., Paciolla, I., Pisano, C., Cecere, S. C., Napoli, M. D., Tambaro, R., Califano, D., Losito, S., Scognamiglio, G., Setola, S. V., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.008 · Cited by 154
Wu, S.-P., Liao, R.-Q., Tu, H., Wang, W., Dong, Z., Huang, S., Guo, W., Gou, L.-Y., Sun, H., Zhang, Q., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.132 · Cited by 154
Radiation Pneumonitis: Old Problem, New Tricks
Jain, V., & Berman, A. T. (2018) · Cancers · doi:10.3390/cancers10070222 · Cited by 154
Metadata
- Authors
- Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén Frontera, O., Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C. T., Lestini, B., & Spigel, D. R.
- Affiliations
- City Of Hope National Medical Center (US)
- The Netherlands Cancer Institute (NL)
- University of Perugia (IT)
- Ruhrlandklinik (DE)
- Russian Cancer Research Center NN Blokhin (RU)
- Moffitt Cancer Center (US)
- University of Chicago (US)
- Oncology Hematology Care (US)
- Duke Medical Center (US)
- Massachusetts General Hospital (US)
- Fakultní nemocnice Bulovka (CZ)
- University Hospital Heidelberg (DE)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Amphia Ziekenhuis (NL)
- Hospital Universitario Virgen del Rocío (ES)
- LungenClinic Grosshansdorf (DE)
- Bristol-Myers Squibb (United States) (US)
- Tennessee Oncology (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-09
- Volume
- 373
- Issue
- 2
- Pages
- 123-135
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4681400
- OpenAlex
- W2156353875
- Cited by
- 8,447
- References
- 22
- Citations by year
- 2026: 204 · 2025: 332 · 2024: 525 · 2023: 627 · 2022: 718 · 2021: 928 · 2020: 1065 · 2019: 969 · 2018: 1066 · 2017: 1001 · 2016: 803 · 2015: 184
- FWCI
- 444.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- nivolumab, docetaxel, squamous cell non-small cell lung cancer, PD-1 inhibitors, immune checkpoint inhibitors, overall survival, progression-free survival, PD-L1 expression, treatment-related adverse events, second-line therapy, previously treated patients, response rate, treatment safety and efficacy comparison, immunotherapy versus chemotherapy
- MeSH terms
- Docetaxel, Nivolumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Immunoglobulin G, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Taxoids, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
